Black Diamond Therapeutics, Inc.
BDTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Black Diamond Therapeutics, Inc. (BDTX) is listed under Biotechnology. At a $121.5M market cap, Black Diamond Therapeutics, Inc. ranks as a micro-cap company within healthcare. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Market Cap
$121.5M
Beta
3.31
P/E (TTM)
—
P/E (Fwd)
-2.12
EPS (TTM)
$-0.75
EPS (Fwd)
$-1.00
ROE
-37.2%
ROA
-19.1%
Cash
$110.5M
Total Debt
$17.0M
Free CF
-$23.6M
52W Change
-31.1%
Annual Financials
Cash vs Debt
Where BDTX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BDTX finished 4.89% below its 150-day moving average ($2.25) and 11.57% below its 200-day moving average ($2.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BDTX overbought or oversold?
At the September 3, 2026 close, BDTX's RSI(14) was 57.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $110.5M in cash and $17.0M in debt, BDTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$23.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -37.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Black Diamond Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, BDTX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Black Diamond Therapeutics, Inc.'s trajectory.